Evidence map›Paper›PMID 36498526›Full record

ArticleJournal of clinical medicine2022

Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial.

Yingying Jiang, Yujun Zhang, Zhaoqiong Zhu, Yidan Huang, Dachun Zhou, Jingchen Liu, Chaoyu Li, Xiangdong Chen, Dingxin Kang, Shoushi Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Yingying JiangDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Yujun ZhangDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhaoqiong ZhuDepartment of Anesthesiology, The First Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Yidan HuangDepartment of Anesthesiology, Liuzhou People's Hospital, Liuzhou 545000, China.
Dachun ZhouDepartment of Anesthesiology, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou 310000, China.
Jingchen LiuDepartment of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Chaoyu LiDepartment of Anesthesiology, The Second People's Hospital of Neijiang, Neijiang 641000, China.
Xiangdong ChenDepartment of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.ORCID 0000-0003-3347-2947
Dingxin KangDepartment of Anesthesiology, The 2th Affiliated Hospital of WMU, Wenzhou 325000, China.
Shoushi WangDepartment of Anesthesiology, Qingdao Central Hospital Group, Qingdao 266000, China.
Jin LiuDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Bin LiuDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Wensheng ZhangDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan University · CNGuangxi Medical University · CNLiuzhou General Hospital · CNNeijiang Normal University · CNQingdao University · CNSir Run Run Shaw Hospital · CNUnion Hospital · CNWenzhou Medical University · CNZunyi Medical University · CN

Funding

National Major Scientific and Technological Special Project for "Significant New Drugs Development" 2016ZX09101066
6 · The paper itself

Abstract

This current phase II clinical trial was to compare the effect and safety of adamgammadex, a new cyclodextrin-based selective relaxant binding agent, with sugammadex to reverse rocuronium-induced neuromuscular block. Patients were randomised to receive adamgammadex (4 or 6 mg kg

Indexed as

adamgammadexmuscle relaxant antagonistperioperative medicinepharmacodynamicsphase II clinical trialsugammadex

Identifiers

PMID36498526
PMCPMC9738056
OpenAlexW4310184782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.